The latest price target for Metagenomi (NASDAQ:MGX) was reported by Chardan Capital on November 20, 2024. The analyst firm set a price target for $15.00 expecting MGX to rise to within 12 months (a possible 803.61% upside). 18 analyst firms have reported ratings in the last year.

The latest analyst rating for Metagenomi (NASDAQ:MGX) was provided by Chardan Capital, and Metagenomi maintained their buy rating.

There is no last upgrade for Metagenomi

The last downgrade for Metagenomi Inc happened on May 2, 2024 when JP Morgan changed their price target from $16 to $6 for Metagenomi Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Metagenomi, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Metagenomi was filed on November 20, 2024 so you should expect the next rating to be made available sometime around November 20, 2025.

While ratings are subjective and will change, the latest Metagenomi (MGX) rating was a maintained with a price target of $15.00 to $15.00. The current price Metagenomi (MGX) is trading at is $1.66, which is out of the analyst’s predicted range.